文献速递神经肿瘤

老年垂体腺瘤:美国手术治疗结果与治疗趋势

Pituitary adenoma in the elderly: surgical outcomes and treatment trends in the United States.
PubMed 文献 · J Neurosurg · 2022-04-29

基于美国国家癌症数据库2004至2016年96,399例垂体腺瘤患者,老年(≥65岁)患者25,464例中53%接受手术、1.9% upfront放疗、44.9%观察。老年手术患者30天死亡1.4% vs 非老年0.6%,90天死亡2.8% vs 0.9%,住院延长26.1% vs 23.0%,次全切除27.2% vs 24.5%。高容量机构结局优于低容量机构。

要点

  • 老年垂体腺瘤患者术后30天和90天死亡率均高于非老年患者。
  • 高容量机构手术结局优于低容量机构。
  • 系统综述22项研究报告老年患者死亡率0.7%,低于NCDB真实世界数据。

核心结论

  • 老年垂体腺瘤患者术后死亡风险高于年轻患者,该风险在既往文献中可能被低估。
  • 在高容量机构手术更能反映历史报告的死亡率,对考虑手术的老年患者有重要意义。

研究设计与样本

  • 基于美国国家癌症数据库(NCDB)的多中心全国登记研究,纳入2004至2016年经MRI(观察病例)或病理(手术病例)诊断的≥18岁垂体腺瘤成人患者,共96,399例,其中老年(≥65岁)患者25,464例。

主要发现

  • 老年患者中53%接受手术,1.9%接受upfront放疗,44.9%观察未治疗。
  • 与非老年患者相比,老年手术患者30天死亡率1.4% vs 0.6%、90天死亡率2.8% vs 0.9%、住院延长(≥5天)26.1% vs 23.0%、次全切除27.2% vs 24.5%(各p≤0.01)。
  • 多因素分析中,年龄、肿瘤大小和Charlson-Deyo合并症评分与术后死亡率独立相关。
  • 高容量机构较低容量机构30天死亡率0.9% vs 1.8%(p<0.001)、90天死亡率2.0% vs 3.5%(p<0.001)、住院延长21.8% vs 30.3%(p<0.001)。
  • 系统文献综述包含22项研究,报告老年垂体腺瘤患者死亡率为0.7%,明显低于NCDB真实世界结局。

关键数值与推荐

  • 与观察相比,接受手术治疗的相关因素包括较年轻年龄、较高收入、私人保险、较高Charlson-Deyo合并症评分、较大肿瘤尺寸和在学术医院接受治疗(各p≤0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 系统文献综述报告老年患者死亡率0.7%,明显低于NCDB真实世界结局,提示既往发表文献存在实质性选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Decision-making in how to manage pituitary adenomas (PAs) in the elderly (age ≥ 65 years) can be challenging given the benign nature of these tumors and concerns about surgical morbidity in these patients. In this study involving a large multicenter national registry, the authors examined treatment trends and surgical outcomes in elderly compared to nonelderly patients. METHODS: The National Cancer Data Base (NCDB) was queried for adults aged ≥ 18 years with PA diagnosed by MRI (in observed cases) or pathology (in surgical cases) from 2004 to 2016. Univariate and multivariate logistic regressions were used to evaluate the prognostic impact of age and other covariates on 30- and 90-day postsurgical mortality (30M/90M), prolonged (≥ 5 days) length of inpatient hospital stay (LOS), and extent of resection. RESULTS: A total of 96,399 cases met the study inclusion criteria, 27% of which were microadenomas and 73% of which were macroadenomas. Among these cases were 25,464 elderly patients with PA. Fifty-three percent of these elderly patients were treated with surgery, 1.9% underwent upfront radiotherapy, and 44.9% were observed without treatment. Factors associated with surgical treatment compared to observation included younger age, higher income, private insurance, higher Charlson-Deyo comorbidity (CD) score, larger tumor size, and receiving treatment at an academic hospital (each p ≤ 0.01). Elderly patients undergoing surgery had increased rates of 30M (1.4% vs 0.6%), 90M (2.8% vs 0.9%), prolonged LOS (26.1% vs 23.0%), and subtotal resection (27.2% vs 24.5%; each p ≤ 0.01) compared to those in nonelderly PA patients. On multivariate analysis, age, tumor size, and CD score were independently associated with worse postsurgical mortality. High-volume facilities (HVFs) had significantly better outcomes than low-volume facilities: 30M (0.9% vs 1.8%, p < 0.001), 90M (2.0% vs 3.5%, p < 0.001), and prolonged LOS (21.8% vs 30.3%, p < 0.001). A systematic literature review composed of 22 studies demonstrated an elderly PA patient mortality rate of 0.7%, which is dramatically lower than real-world NCDB outcomes and speaks to substantial selection bias in the previously published literature. CONCLUSIONS: The study findings confirm that elderly patients with PA are at higher risk for postoperative mortality than younger patients. Surgical risk in this age group may have been previously underreported in the literature. Resection at HVFs better reflects these historical rates, which has important implications in elderly patients for whom surgery is being considered.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Chalif EJ, Morshed RA, Young JS, et al. Pituitary adenoma in the elderly: surgical outcomes and treatment trends in the United States. J Neurosurg. 2022. PMID: 35535847. doi:10.3171/2022.3.JNS212940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。